Keri Dorn

Title: Keri Dorn: Innovator in Anti-Staphylococcal Treatments

Introduction

Keri Dorn is a prominent inventor based in Spring House, PA (US). She has made significant contributions to the field of medical science, particularly in the development of innovative treatments for bacterial infections. With a total of 2 patents, her work focuses on addressing the challenges posed by staphylococcal infections.

Latest Patents

Keri Dorn's latest patents include compositions and methods for phagocyte delivery of anti-staphylococcal agents. This application relates to multi-specific molecules that bind to multiple bacterial virulence factors. The binding molecules consist of at least two binding domains, which include an antibody or antibody fragment and an alternative scaffold. The first binding domain targets a glycosylated staphylococcal surface protein, while the second binding domain is designed to bind to a staphylococcal leukotoxin. These multi-specific binding compounds exhibit killing activity against staphylococci, making them valuable in the treatment and amelioration of infections, including those caused by methicillin-resistant strains.

Career Highlights

Throughout her career, Keri Dorn has worked with esteemed organizations such as New York University and Janssen Biotech, Inc. Her experience in these institutions has allowed her to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Keri has collaborated with notable colleagues, including Victor J Torres and Randall J Brezski. These partnerships have further enhanced her research and development efforts in combating bacterial infections.

Conclusion

Keri Dorn's innovative work in the field of anti-staphylococcal treatments showcases her dedication to improving healthcare outcomes. Her patents and collaborations reflect her commitment to advancing medical science and addressing critical health challenges.